Dr. Bonkovsky Discusses Afamelanotide EPP Care

Afamelanotide protects patients with erythropoietic protoporphyria by increasing natural skin pigment rather than by lowering protoporphyric production.

Key Clinical Takeaways:

• Afamelanotide increases skin pigmentation to protect against light exposure in erythropoietic protoporphyria (EPP) patients.
• Geographic availability and high drug prices present major barriers for patients seeking treatment.
• Managing long-term complications requires coordination across primary care, dermatology, and hepatology specialists.

Skin Pigment Influences Afamelanotide Efficacy and Risk

Dr. Bonkovsky explained that afamelanotide functions by raising natural skin pigment. Biological skin tone directly influences baseline severity. African Americans generally experience milder forms of EPP and X-linked protoporphyria due to abundant eumelanin. Fair-skinned individuals, particularly patients with red hair and freckles who cannot tan, tend to fare worse.

Availability and Access Hurdles

Access remains the primary obstacle for individuals prescribed chronic afamelanotide therapy. Very few medical sites across the United States hold authorization to administer the drug. Patients frequently travel hundreds of miles to receive treatment. High financial costs have triggered pushback from pharmacy benefit managers and insurance providers. While physical side effects occur, logistical convenience and drug availability dictate real-world treatment patterns far more than adverse events.

Oral Alternatives Offer Less Burden than Implants

Dr. Bonkovsky suspects that patients receiving chronic afamelanotide routinely skip winter doses and restart treatment in the spring, a practice he considers reasonable given the seasonal nature of light exposure. Oral therapeutic alternatives such as dersimelagon and bitopertin offer a much more appealing daily format. These oral options must still clear regulatory hurdles with the Food and Drug Administration and will likely carry substantial price tags. Even with high costs, a single daily pill imposes significantly less burden than an implant administered every other month.

Hepatologists Must Monitor Advanced Liver Injury

Dermatologists often lack the specific interest or clinical expertise required to manage every manifestation of erythropoietic protoporphyria. Primary care physicians and pediatricians should share management duties for vitamin D deficiency and liver health. Patients showing signs of significant liver injury require evaluation by a hepatologist at least twice a year. Advanced protoporphyric hepatopathy can progress rapidly toward jaundice and liver failure. Managing these severe crises demands specialized interventions like hypertransfusion, plasmapheresis, and intravenous heme administered at a porphyria center of excellence.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.